In the last trading session, 3.69 million MaxCyte Inc (NASDAQ:MXCT) shares changed hands as the company’s beta touched 0. With the company’s per share price at $2.18 changed hands at -$0.1 or -4.39% during last session, the market valuation stood at $231.78M. MXCT’s last price was a discount, traded about -141.28% off its 52-week high of $5.26. The share price had its 52-week low at $2.10, which suggests the last value was 3.67% up since then.
Analysts gave the MaxCyte Inc (MXCT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended MXCT as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. MaxCyte Inc’s EPS for the current quarter is expected to be -0.1.
MaxCyte Inc (NASDAQ:MXCT) trade information
Instantly MXCT was in red as seen at the end of in last trading. With action -0.91%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -47.60%, with the 5-day performance at -0.91% in the red. However, in the 30-day time frame, MaxCyte Inc (NASDAQ:MXCT) is -15.18% down.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 63.67% from its current market value. According to analyst projections, MXCT’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -175.23% plunge from its current level, while the stock would need to soar -175.23% for it to hit the projected low.
MaxCyte Inc (MXCT) estimates and forecasts
Year-over-year growth is forecast to reach 6.85% up from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 9.57M. 5 analysts are of the opinion that MaxCyte Inc’s revenue for the current quarter will be 10.46M. The company’s revenue for the corresponding quarters a year ago was 10.43M and 8.16M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -8.25%. The estimates for the next quarter sales put growth at 28.06%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -11.37%. The 2025 estimates are for MaxCyte Inc earnings to increase by 8.33%, but the outlook for the next 5-year period is at 9.40% per year.
MXCT Dividends
MaxCyte Inc is expected to release its next quarterly earnings report in June.
CADIAN CAPITAL MANAGEMENT, LP holds the second largest percentage of outstanding shares, with 7.285% or 7.62 million shares worth $29.88 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 2.81 shares estimated at $6.13 million under it, the former controlled 2.64% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.60% of the shares, roughly 2.77 shares worth around $6.04 million.
